No products in the cart.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
CAN PDE5 INHIBITORS BE COPRESCRIBED WITH NITRATES?
Combining phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) with oral nitrate medications is formally contraindicated due to risk for hypotension and other severe adverse cardiac events. Nonetheless, in Denmark, prescription of PDE5 inhibitors to patients who were taking oral nitrates for ischemic heart disease (IHD) increased 20-fold from 2000 to 2018. Using nearly 20 years of nationwide data, Danish investigators examined associations between PDE5 use and adverse cardiovascular outcomes. Risk for two composite cardiac outcomes — (1) cardiac arrest, shock, myocardial infarction, stroke, or acute coronary arteriography; and (2) syncope, angina, or drug-related adverse event — were not significantly different among patients who received nitrates versus those who did not.
Full Access: NEJM
FDA APPROVES OTESECONAZOLE FOR CHRONIC YEAST INFECTIONS
The US Food and Drug Administration (FDA) has approved oteseconazole capsules (Vivjoa), an azole antifungal agent for the prevention of recurrent yeast infections in females who are not of reproductive potential. It is the first FDA-approved product for the treatment of recurrent vulvovaginal candidiasis.
Full Access: Medscape
VALNEVA AND PFIZER REPORT POSITIVE PHASE 2 DATA FOR LYME DISEASE VACCINE IN CHILDREN
Pediatric data for their Lyme disease vaccine candidates, VLA15 shows positive results, and now plan to include this population in an upcoming Phase 3 trial. Data showed that VLA15’s immunogenicity was more evident in children between the ages of 5 and 17 years old, compared with adults ages 18 to 65 who underwent similar vaccination schedules.
Full Access: Biopharma
MORE EVIDENCE LINKS ASTHMA SEVERITY TO AGE OF ONSET
The recent multinational retrospective cohort study, published in The Journal of Allergy and Clinical Immunology: In Practice, combined national electronic health records databases from five different countries—the United Kingdom, Spain, Italy, the Netherlands, and Denmark—that included 586,436 adult asthma patients. This study may be the largest to date that’s found the age of asthma onset is an integral factor in defining the severity of disease and the frequency of comorbidities.
Full Access: Medscape
Notifications
